Interestingly, a good separation was also observed between t(15;17) AML blasts and normal neutrophil-committed CD13+ HPCs (tube 1 of the EF AML/MDS panel), normal monocyte-committed CD64+ HPCs (tube 2 of the EF AML/MDS panel), and normal erythroid-committed CD36+ CD71+ CD33− HPCs (tube 3 of the EF AML/MDS panel). This evidence concerns the gene CD33 and acute myeloid leukemia.